NPC
EPRS

National Planning Corporation’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

National Planning Corporation’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-101
Closed -$590 – 2800
2014
Q4 		$590 Buy
+101
New +$528 ﹤0.01% 2761

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

National Planning Corporation's EPRS Position: Q1 2015 in Review

National Planning Corporation sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q1 2015, closing a stake of 101 shares — an estimated $590 sold.

National Planning Corporation first reported a position in EPRS in Q4 2014 and held it in 1 quarter. The position peaked at $590 in Q4 2014. 47 funds tracked by Wall St. Rank hold EPRS as of Q1 2015.

  • National Planning Corporation reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q1 2015 after selling out during the quarter.
  • National Planning Corporation sold 101 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q1 2015, an estimated $590.
  • National Planning Corporation first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q4 2014 and held it in 1 quarter.
  • National Planning Corporation's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $590 in Q4 2014.
  • 47 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q1 2015.

Based on National Planning Corporation's 13F filing for Q1 2015, filed 12 May 2015.